• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[C-原癌基因蛋白2、表皮生长因子受体、p53和增殖细胞核抗原。近期肿瘤标志物对淋巴结阴性乳腺癌的预后意义]

[C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer].

作者信息

Schönborn I, Minguillon C, Lichtenegger W, Zschiesche W, Spitzer E

机构信息

Frauenklinik Universtätsklinikum Rudolf Virchow, Standort Charlottenburg, Freie Universitt Berlin.

出版信息

Geburtshilfe Frauenheilkd. 1995 Oct;55(10):566-71. doi: 10.1055/s-2007-1023525.

DOI:10.1055/s-2007-1023525
PMID:8543129
Abstract

In 216 breast cancer patients, the prognostic value of current biological factors (c-erbB-2, EGF-receptor, p53, PCNA-proliferative fraction) was compared with that of conventionally histomorphologic features (histologic type, histologic grade, tumour size, hormonal receptor status). After a 66(6 - 109) months' median follow-up survival was significantly correlated with histological grade (p = 0.014) and PCNA-proliferative activity (p = 0.015). The prognostic influence of oestrogen receptor (ER)- and progesteron receptor (PR-)status achieved borderline significance (ER/p = 0.07; PR/p = 0.05). Neither c-erbB-2, EGF-R, p53 nor any of the other factors showed any correlation to survival. In the multivariate analysis, histological grade was revealed as the only independent prognostic factor. The prognostic value of PCNA was second to histological grade and if grade was excluded from the analysis, PCNA-expression became the only independent factor. Thus, in individual cases the PCNA-proliferative fraction could help the clinician to decide on the therapy.

摘要

在216例乳腺癌患者中,对当前生物因子(c-erbB-2、表皮生长因子受体、p53、增殖细胞核抗原增殖分数)的预后价值与传统组织形态学特征(组织学类型、组织学分级、肿瘤大小、激素受体状态)的预后价值进行了比较。经过66(6 - 109)个月的中位随访,生存率与组织学分级(p = 0.014)和增殖细胞核抗原增殖活性(p = 0.015)显著相关。雌激素受体(ER)和孕激素受体(PR)状态的预后影响达到临界显著性(ER/p = 0.07;PR/p = 0.05)。c-erbB-2、表皮生长因子受体、p53以及其他任何因素均未显示与生存率有任何相关性。在多变量分析中,组织学分级被揭示为唯一的独立预后因素。增殖细胞核抗原的预后价值仅次于组织学分级,若在分析中排除分级因素,增殖细胞核抗原表达则成为唯一的独立因素。因此,在个别病例中,增殖细胞核抗原增殖分数可为临床医生的治疗决策提供帮助。

相似文献

1
[C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer].[C-原癌基因蛋白2、表皮生长因子受体、p53和增殖细胞核抗原。近期肿瘤标志物对淋巴结阴性乳腺癌的预后意义]
Geburtshilfe Frauenheilkd. 1995 Oct;55(10):566-71. doi: 10.1055/s-2007-1023525.
2
Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.影响原发性乳腺癌手术切除后无病生存率的预后因素。
Eur J Histochem. 2001;45(1):73-84. doi: 10.4081/1616.
3
[Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].[免疫组织化学检测受体、组织蛋白酶、肿瘤抑制蛋白和增殖标志物作为原发性乳腺癌预后指标的价值]
Geburtshilfe Frauenheilkd. 1996 Apr;56(4):177-83. doi: 10.1055/s-2007-1022256.
4
Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.雌激素和孕激素受体与乳腺癌患者病理及分子预后因素的整合
J Steroid Biochem Mol Biol. 1998 Dec;67(5-6):431-7. doi: 10.1016/s0960-0760(98)00140-x.
5
The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.对于淋巴结阴性乳腺癌患者,p53和c-erb B-2免疫染色的预后价值被高估:对613例患者进行14至30年随访的预后因素多变量分析
Cancer. 2000 Feb 15;88(4):804-13. doi: 10.1002/(sici)1097-0142(20000215)88:4<804::aid-cncr11>3.0.co;2-y.
6
Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.对DNA倍体、p53、c-erbB-2蛋白、表皮生长因子受体(EGFR)和类固醇激素受体进行多变量分析,以预测乳腺癌短期预后不良。
Anticancer Res. 1997 Mar-Apr;17(2B):1417-23.
7
Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein.通过BrdU和PCNA评估乳腺癌中的增殖活性。与p53、c-erbB-2、雌激素受体和P-糖蛋白表达的相关性。
Pathol Res Pract. 1995 Nov;191(11):1122-32. doi: 10.1016/s0344-0338(11)80657-6.
8
The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma.p53和c-erbB-2表达、增殖活性及血管生成在淋巴结阴性乳腺癌中的预后价值
Tumori. 2005 Jan-Feb;91(1):46-52. doi: 10.1177/030089160509100109.
9
C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk.原发性乳腺癌中C-erbB-2的过度表达:高危患者的独立预后因素。
Breast Cancer Res Treat. 1994;29(3):287-95. doi: 10.1007/BF00666483.
10
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.在接受多柔比星和环磷酰胺序贯紫杉醇辅助化疗的III期乳腺癌患者中,bcl-2表达的预后意义
BMC Cancer. 2007 Apr 12;7:63. doi: 10.1186/1471-2407-7-63.